Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 17/20 | 0.60 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134063 | 0.88 | PGR (0.58) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6426704 | 0.82 | PGR (0.71) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4103914 | 0.82 | PGR (0.50) | PGRPARP1PARP2 | |
| SCHEMBL4103911 | 0.82 | PGR (0.50) | PGRPARP1PARP2 | |
| SCHEMBL6424665 | 0.81 | PGR (0.67) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3520506 | 0.80 | PGR (0.72) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3523715 | 0.80 | PGR (0.77) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3521176 | 0.79 | PGR (0.73) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3521615 | 0.77 | PGR (0.70) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3521572 | 0.77 | PGR (0.52) | PGRPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515680-A4 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1531806-A4 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1531806-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1515680-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | claimed |
| WO-2004000225-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| WO-2004000227-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | GPER1, OXTR, SHBG | PGR 44/4885PDE4A 4239/4885PDE4B 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.